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Abstract 
Background: In Qatar, the National Vision 2030 and the National Health 
Strategy 2018-2022 articulate the need to improve healthcare delivery by better 
utilisation of the skilled workforce. In this regard, pharmacy practice is rapidly 
advancing and several extended pharmacy services are now available in 
institutionalised settings. 
Objective: This study aimed to determine health-related stakeholders’ 
perceptions of current clinical pharmacy services in Qatar, and the potential 
development and implementation of further patient-centred roles. 
Setting: All major organisations and institutions relating to the practice, 
education, regulation, and governance of pharmacy in Qatar. 
Method: Qualitative, face-to-face semi-structured interviews were conducted 
with individuals in key strategic positions of policy development and influence 
(i.e. health-related academic leaders, healthcare policy developers, directors of 
medicine/pharmacy/nursing, and patient safety leaders). Participants were 
recruited via a combination of purposeful and snowball sampling, until the point 
of data saturation was reached. The interview guide was grounded in the 
Consolidated Framework for Implementation Research domains of innovation 
characteristics, outer and inner setting, characteristics of individuals, and 
implementation process. The interviews were digitally recorded, transcribed and 
independently analysed by two researchers using the Framework approach. 
Main outcome measure: Perceptions of stakeholders regarding current and 
potential for future clinical pharmacy services in Qatar. 
Results: Thirty-seven interviews were conducted with stakeholders of policy 
influence in healthcare. The interviewees reported a variety of clinical pharmacy 
services available in Qatar, which they perceived as positively impacting patient 
care outcomes, pharmacists’ professional autonomy, and the healthcare system 
in general (innovation characteristics). However, they perceived that these 
services were mainly performed in hospitals and less in community pharmacy 
setting (inner setting) and were undervalued by patients and the public (outer 
setting). Expansion of pharmacists’ clinical activities was supported, with 
recognition of facilitators such as the skillset and training of pharmacists, 
potential time release due to automation and well-considered implementation 
processes (characteristics of individuals, inner setting, process). 
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Conclusion: Health-related stakeholders in Qatar have positive perceptions of 
current clinical pharmacy services and support the expansion of pharmacist’s 
roles. However, service development needs to consider the issues of patient and 
public awareness and initially target institutionalised healthcare settings.  
 
Impact of findings on practice 
• In Qatar, pharmacy practice is rapidly advancing and several extended 
clinical pharmacy services are now available in institutionalised healthcare 
settings. 
• However, limited evidence is available to explore how key health-related 
stakeholders perceive these services including the potential development 
and implementation of new patient-centred pharmacist’s roles. 
• Findings of this research could facilitate cognitive pharmaceutical service 
development and better provision of patient-centered care, which could be 
transferrable to other countries, especially from the context of the Middle 
East.  
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Introduction 
The evolution from product focused pharmacy services to more patient-centred 
pharmacy services was articulated in World Health Organization (WHO) policy 
documents advocating better use of pharmacists’ skills to improve health care.1-3 
Similarly, the International Pharmaceutical Federation (the global body 
representing pharmacy, pharmaceutical sciences and pharmaceutical education) 
advocates the systematic development and implementation of more clinical 
patient-centred and outcomes-oriented services.4,5 
 
Several countries have well-developed clinical pharmacy services which are part 
of routine practice. For instance, in the United Kingdom (UK), clinical pharmacy 
services have evolved from rarely providing therapeutic drug monitoring and 
medication history-taking to the introduction of supplementary prescribing in 
2003 and independent prescribing in 2006.6,7 The majority of literature 
evaluating pharmacist prescribers’ practice demonstrates safety, the 
achievement of clinical outcomes comparable to physicians8,9 and acceptability 
by a range of key health stakeholders.10,11 In 2015, the UK launched an 
ambitious plan aiming to embed clinical pharmacists within general medical 
practices.12,13 An independent evaluation based on pilot data from England 
confirms the significant contribution to patient safety, supporting long-term 
condition management, and improving medication knowledge within the team14. 
Similar positive results have been reported in Scotland, where pharmacists are 
now practising within one-third of general medical practices.15 
 
Over the past decade, Qatar has taken steps to transform its healthcare system. 
The Qatar National Vision 2030 aims to “transform Qatar into an advanced 
country by 2030, capable of sustaining its own development and providing for a 
high standard of living for all of its people for generations to come” by 
“balancing the accomplishments that achieve economic growth with the human 
and natural resources”.16 To realise the ambitions of the National Vision for a 
healthy population, the National Health Strategy was launched in 2011.17 Six 
projects were initiated, one of which aimed to strengthen the role of pharmacists 
in supporting patients, as well as improving the quality of healthcare system by 
making it more accessible and less costly. Recently, the Ministry of Public Health 
reinforced the shift in care provision from secondary and tertiary care to primary 
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care in an updated National Health Strategy 2018-2022, “Our Health, Our 
Future: Improved health for Qatar’s population, meeting the needs of existing 
and future generations”.18   
 
Healthcare in Qatar is provided through government-funded and private-
provided secondary and tertiary institutions, government-funded primary 
healthcare centres and private sector centres (ambulatory care), and community 
pharmacies (Figure 1).19  
 
 
Figure 1: Healthcare system in Qatar20 
 
Hamad Medical Corporation (HMC) is the largest provider of healthcare in Qatar, 
and is regarded as one of the leading hospital services providers in the Middle 
East region. HMC manages 12 hospitals – nine specialist hospitals and three 
community hospitals – as well as the National Ambulance Service and home and 
residential care services.21 In 2016, HMC became the first healthcare system 
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Pharmacy practice in Qatar has advanced in recent years due to multiple factors 
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therapeutic range and reduced percentage of visits with extreme subtherapeutic 
international normalized ratio (INR).22,26 Therefore, pharmacy practice is rapidly 
advancing and several extended pharmacy services are now available in 
institutionalised settings in Qatar. There, however, remains potential for 
expanding further clinical pharmacy services to all sectors of practice. Obtaining 
the perceptions of key decision-makers (stakeholders) would facilitate plans for 
expansion. 
 
Aim of the study 
This study aimed to determine health-related stakeholders’ perceptions of 
current clinical pharmacy services in Qatar, and the potential development and 
implementation of further patient-centred roles. 
 
Ethics approval 
Ethical approval was granted by Robert Gordon University School of Pharmacy 
and Life Sciences Research Ethics Committee (Approval reference S64), Ministry 
of Public Health Ethics Committee, Hamad Medical Corporation Medical Research 
Committee (Approval reference MRC0449/2017), and Qatar University 
Institutional Review Board (Approval reference QU-IRB 772-E/17).  
 
Methods 
Study design 
This study utilised a qualitative approach of semi-structured interviews with key 
stakeholders. A qualitative methodology was selected to generate in-depth, rich 
data allowing detailed description and understanding of perceptions around 
clinical pharmacy practice in Qatar.27 
 
Setting 
Data generation took place across all major organisations and institutions 
relating to the practice, education, regulation, and governance of pharmacy 
practice in Qatar. These comprised of the Ministry of Public Health; primary, 
secondary and tertiary healthcare institutions; community pharmacies; and all 
healthcare academic institutions providing pharmacy, medical, nursing, and 
pharmacy technician education programmes. 
 
7 
 
Inclusion and exclusion criteria 
The intention was to generate data representing all key stakeholder groups, with 
policy influence relating to the development, implementation and evaluation of 
clinical models of care. The groups targeted were individuals in key strategic 
positions of policy influence (i.e. health-related academic leaders, healthcare 
policy developers, directors of medicine/pharmacy/nursing, and patient safety 
leaders). Members of the research team based in Qatar, who might have 
satisfied the above criteria, were excluded from the study. 
 
Sampling and sampling approach 
The sampling frame included all individuals meeting the inclusion and exclusion 
criteria. The names and contact details of all potential participants were collated 
by the research team members using their professional networks. Purposive 
sampling was employed to capture those individuals who were most likely to 
contribute to the achievement of the research objectives. Snowball sampling was 
also utilised to ensure that no key individuals had been omitted by asking each 
interviewee to recommend others that they thought were important to include. 
Sample size was determined to achieve data saturation according to the steps 
outlined by Francis et al.28 Five members from each professional group were 
interviewed as the initial analysis sample. This sample was believed to represent 
adequate diversity based on the participants’ professions. Afterwards, one 
additional interview was performed for each professional group before the 
stopping criterion was tested. Responses were coded and analysed 
independently by two research team members in order to confirm that data 
saturation was achieved. 
 
Development of interview guide 
The semi-structured interview guide was constructed based on a review of the 
published literature on pharmacy practice and grounded in the Consolidated 
Framework for Implementation Research (CFIR).29 This theoretical framework 
was used to ensure that all relevant implementation factors that can determine 
the success or failure of any innovation are deliberated. The guide was 
developed and mapped against the five main domains of CFIR: innovation 
characteristics (of the intervention being implemented into a particular 
organisation), outer setting (i.e. economical, political, and social context within 
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which an organisation resides), inner setting (i.e. structural, political, and 
cultural context through which implementation process will proceed), 
characteristics of individuals (who will enact the intervention), and process (of 
implementation).29 The interview guide included questions related to 
participants’ awareness of current clinical roles performed by pharmacists in 
Qatar, their views on the efficiency of these services and any potential roles 
pharmacists in Qatar can perform in the future. The guide was reviewed for 
dependability, which is the degree to which different researchers are able to 
produce the same data,30 by members of the research team prior to piloting with 
five academic and practice-based stakeholders. This pilot process did not lead to 
any major changes to the guide. Pilot interviews were not included in the 
dataset.  
 
Data generation 
All potential participants were e-mailed the information leaflet, with a reminder 
sent two weeks later if no response had been received. The interviews were 
conducted from April to August 2017 by one of the research team members (TJ) 
who was trained in conducting qualitative research. Written, informed consent 
was obtained from all research participants before commencing. Interviews, of 
approximately 45-60 minutes, were audio-recorded and later transcribed by TJ 
and reviewed for accuracy by DS. All interviewees were offered the opportunity 
to review the transcripts to promote credibility and dependability.30 
 
Data analysis 
Thematic analysis was conducted using the framework approach following the 
steps outlined by Ritchie and Spencer31. All interviews were input into NVivo® 
software then initially coded by TJ based on the different constructs of the CFIR 
before being examined for further sub-themes within each construct. Afterwards, 
the emerging themes were reviewed against the original data then indexed and 
refined. The analysis was reviewed by another team member to ensure 
credibility, with any disagreements resolved through discussion. 
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Results 
Stakeholders recruitment 
Out of 74 stakeholders invited, 37 interviews were conducted to reach data 
saturation in each stakeholder group giving representation of all practice settings 
(Table 1).  
 
Table 1: Characteristics of included stakeholders according to practice setting 
Stakeholders’ category Setting: Number of participants* 
Academic Leaders • Medicine: 2 
• Pharmacy and Pharmacy technician: 5 
• Nursing: 2 
Healthcare Policy Developers • Primary care/Community: 1 
• Secondary care: 1 
• Tertiary care: 2 
• Corporate/Ministry: 2 
Medical Practice Leaders • Primary care/Community: 1 
• Secondary care: 3 
• Tertiary care: 5 
• Corporate/Ministry: 1 
Pharmacy Practice Leaders • Primary care/Community: 3 
• Secondary care: 1 
• Tertiary care: 3 
• Corporate/Ministry: 1 
Nursing Practice Leaders • Secondary care: 1 
• Tertiary care: 5 
• Corporate/Ministry: 3 
Patient Safety Advocates • Primary care/Community: 1 
• Secondary care: 1 
• Tertiary care: 4 
* Some held multiple roles within their organisation 
 
Key themes that emerged from the interviews 
Themes which emerged during the interviews were mapped to the different CFIR 
domains. The major themes frequently highlighted by interviewees are described 
in more details below while the rest are summarised in Table 2. There were no 
marked differences in responses across the professional groupings. 
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Table 2: A summary of the CFIR domains and constructs relating to views and perspectives on pharmacy practice in Qatar 
CFIR domain CFIR constructs Key themes Illustrative quotes 
Innovation 
characteristics 
of the 
intervention 
being 
implemented 
into a particular 
organisation 
Evidence 
strength and 
quality 
Perceptions on 
quality and 
validity of 
evidence 
supporting the 
innovation 
The expansion of the numbers of clinical pharmacist within 
HMC was considered to be an indication of effectiveness, 
efficiency and acceptability. 
“I don’t really have the statistics but the number of clinical pharmacists 
now in Hamad [Hamad General Hospital] is really big. We started only 
with 10. Today maybe we are talking about 60-70 pharmacists. So why 
did we have this expansion if the role is not really important?” 
                      Academic Leader 3 
Outer setting 
i.e. economical, 
political, and 
social context 
within which an 
organisation 
resides 
Needs and 
resources 
Extent to which 
patient needs are 
known and 
prioritised 
There was a feeling that the general public was not aware of 
the skillset and roles of pharmacists and that this could act 
as a barrier to expanding scope of practice. 
“Patients are barriers because they don’t really value the role of the 
pharmacist… Anytime you speak about pharmacist, shop keeper image 
pops to their mind.” 
Academic Leader 1 
Inner setting 
i.e. structural, 
political, and 
cultural context 
through which 
implementation 
process will 
proceed 
Networks and 
Communications 
Nature and quality 
of networks and 
communications 
within the 
organisation 
There were mixed views on the degree of integration of the 
pharmacist within the multidisciplinary team and therefore 
the communication networks in operation. 
“I have really good relationship here with my pharmacist as well. We have 
dialogue with regard to if there is any issue with nurses and administration 
for instances as well.”          Nursing Practice Leader 3 
“In the psychiatric hospital, the pharmacist was always in a little back 
room. And not on the floor at all.”    Academic Leader 8 
Trust, relationships and communication were thought key to 
the anticoagulation clinic. 
“From the beginning we had very strong and very positive relationship 
with the medical directors…They are trusting me a lot. Building the trust 
and having good relationships with the team will facilitate everything.” 
     Pharmacy Practice Leader 6 
Culture 
Norms, values and 
basic assumptions 
of the organisation 
Despite the positive developments in clinical practice in 
HMC, there was still the view that pharmacists were 
generally undervalued.  
“I suspect that there is a traditional view about the dispensing type 
pharmacist rather than that understanding of them having the kind of 
clinical background knowledge as well.”        Nursing Practice Leader 1 
One factor thought contributing to this lack of awareness 
and lack of value was the large number of expatriated 
health professionals. 
“We have physicians from very different backgrounds and parts of the 
world and all the different cultural heritages and there are sometimes 
adjustments needed to understand that other professional groups are just 
as valuable as their professional group is.”      Medical Practice Leader 1 
Implementation 
climate 
Absorptive capacity 
for change 
Tension for 
change 
Almost all acknowledged that while clinical 
practice had developed, there was potential 
for further developments. 
“Definitely there is a lot of room for improvement. There has been quite a 
lot of changes to the pharmacist role but there is a lot of space for further 
improvement.”     Academic Leader 1 
Relative 
priority 
Developments in clinical practice were felt to 
align to the Qatar National Vision hence were 
considered beneficial. 
“…It will relieve the physician time a little bit… I think this is a very 
important part to be considered in the priorities of the national health over 
here.”           Academic Leader 6 
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Readiness for 
implementation 
Tangible and 
immediate 
indicators of 
organisational 
commitment to 
implementation 
Leadership 
engagement 
The support of the pharmacy leaders was 
considered a main influential factor in clinical 
development. 
“I think the Director of Pharmacy, she is really a pioneer in introducing this 
programme [clinical pharmacy] into Women’s Hospital. This started I think 
seven years ago and now we have very good clinical pharmacists who are 
eager to work and to do further responsibilities.” 
         Medical Practice Leader 3 
Available 
resources 
There was a perception that the current 
number of skilled clinical pharmacists was a 
barrier to further service development. 
“You may have enough [pharmacists] but you need specific skills, you 
need people with clinical practice, competencies and clinical background. 
Qatar lacks the number of clinically qualified and skilled professionals.” 
          Pharmacy Practice Leader 6 
This was noted to be a particular issue during 
times of staff absences. 
“If you have only one pharmacist covering the service, it gets difficult 
sometimes when they need to be on leave for conference or vacation.  
            Academic Leader 6 
Characteristics 
of individuals 
Involved in 
enacting the 
intervention 
Knowledge and 
beliefs about the 
innovation 
Individuals’ 
attitudes and value 
placed on 
innovation 
There was general agreement that, given their education 
and training, pharmacists should be maximising their input 
to patient care. 
“When I look at the education of pharmacists, I think they should be 
working to full scope… I think by maximising their scope, it is better for 
the system and it is better for the patients.”  
     Academic Leader 9 
Self-efficacy 
Individual beliefs in 
their own 
capabilities 
There was recognition that while some pharmacists were 
motivated to develop their clinical practice, there were many 
likely to be less so. 
“Pharmacy like any other profession, you will find the group of people who 
are really motivated to do more work, love the profession, would like to 
serve more …and other pharmacists who are still [not].” 
     Academic Leader 3 
Notably those involved in establishing the anticoagulation 
clinic were highly committed despite their existing workload. 
“The people I had on the team were very committed and enthusiastic to 
the project despite being already overwhelmed with their original work. 
They were working very hard and they were very proud.”  
 Pharmacy Practice Leader 6 
Other personal 
attributes 
Broad construct to 
include other 
traits such as 
motivation, value, 
competence, 
capacity and 
learning style 
The personal development of the pharmacists in Qatar was 
appreciated and thought related to their extensive training, 
and rigid recruitment and licensing standards. 
“I think they improved a lot from maybe 17-18 years ago. There is a lot of 
improvements in pharmacy practice and we appreciate that there is this 
change and improvement.”   Healthcare Policy Leader 6 
“We have a very tight process for recruiting pharmacists so we are looking 
for quality first. So we have very good quality pharmacists with us.” 
                Pharmacy Practice Leader 2 
There was, however, recognition that practice in community 
pharmacy centred on dispensing. 
“The role that is played by the community pharmacists in Qatar is still the 
traditional role in which they just sell medications and maybe provide 
some recommendations or counselling from time to time.” 
    Academic Leader 3 
Process 
of 
implementation 
Planning 
Degree to which a 
scheme or method 
for implementation 
are developed in 
advance 
When developing and implementing clinical pharmacy 
services, there were several key factors for successful 
implementation such as the need for communication with 
other health professionals. 
“From the beginning, before we started anything, we communicated in a 
very nice way with the physicians… So none of the physicians felt 
threatened… We were very scientific, very friendly with them.” 
   Pharmacy Practice Leader 6 
Establishing clear guidelines during the development of the 
anticoagulation clinic and continuous monitoring after 
implementation were cited as being important. 
“We developed the guidelines for all of the anticoagulants and antiplatelets 
and we decided on and approved the workflow as well… And then we 
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started and we continued monitoring the work, take feedback from 
physicians and from patients to improve the process.”  
    Pharmacy Practice Leader 6 
Engaging (Key 
stakeholders) 
Attracting and 
involving 
appropriate 
individuals in 
implementation 
and use of 
innovation 
The need to engage the right key stakeholders as part of 
implementation was highlighted. 
“And the consultant here was very happy about this idea and he supported 
it especially since he came from Canada and he knew how the system was 
running and he supported this. Otherwise it wouldn’t have worked.” 
      Patient Safety Advocate 4 
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Interviewees noted a significant evolution in clinical pharmacy services in Qatar, 
illustrated by the continuous implementation of new services such as the 
pharmacist-run anticoagulation clinic with advantages to patients and 
pharmacists themselves (CFIR domain: innovation characteristics). These 
developments were perceived as being carefully planned with clear 
communications, guidelines, and monitoring processes (CFIR domain: process). 
The interviewees perceived that these services were mainly performed in 
hospitals and less in community pharmacy setting (CFIR domain: inner setting). 
However, a lack of patient and public awareness regarding clinical pharmacy 
activities was also highlighted (CFIR domain: outer setting). In addition, some 
stakeholders reported that the majority of clinical pharmacy services were 
performed exclusively in hospitals with community pharmacy setting mainly 
focused on traditional pharmacist’s product-oriented role of drugs dispensing. 
Nevertheless, the interviewees highlighted the potential for further development, 
aligned to the Qatar National Vision and supported by healthcare leaders (CFIR 
domain: inner setting). They also commented on the quality of the education 
and training of pharmacists and the strict licensing requirements to practice in 
Qatar (CFIR domain: characteristics of individuals). 
 
Given that most discussion (based on counts and depth of discussion) centred on 
specific CFIR domains and constructs, these are considered in more detail. These 
were: innovation source (perception of key stakeholders about whether the 
intervention is externally or internally developed); relative advantage 
(stakeholders’ perception of the advantage of implementing the intervention 
versus an alternative solution); design quality and packaging (perceived 
excellence in how the intervention is bundled, presented, and assembled); 
structural characteristics (the social architecture, age, maturity, and size of an 
organization); and compatibility (the degree of tangible fit between meaning and 
values attached to the intervention by involved individuals, how those align with 
individuals’ own norms, values, and perceived risks and needs, and how the 
intervention fits with existing workflows and systems). 
 
Innovation characteristics  
In terms of the innovation of clinical pharmacy practice, there was recognition 
that this was developing at pace, particularly within HMC. There was description 
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of the clinical pharmacy service in general and exemplified through specialist 
activities such as the pharmacist-led anticoagulation clinic. 
 
1. Innovation source 
There was recognition that the anticoagulation service had developed 
significantly in recent years. This was expressed by participants from all 
stakeholder groups. 
“The clinical pharmacists’ role has developed quite significantly in recent 
years like, for example, in [Name] Hospital there is the anticoagulation clinic 
that is run by pharmacists.”    Academic Leader 1 
 
The clinical service had extended to allow dose adjustment. 
“We call it the anticoagulation clinic where the clinical pharmacists are on the 
front line, meeting the patients…checking the INR and then adjusting the 
dose, so they make the decision.”   Medical Practice Leader 5 
 
There was recognition of other HMC clinical services.  
“Also in clozapine clinic in mental health, there is a direct contact with the 
patient for monitoring the side effects and recording if require changing the 
dose…”       Pharmacy Practice Leader 4 
 
2. Relative advantage 
Clinical practice was perceived to bring advantages including professional 
autonomy, which was considered important to further developments.  
“… it will give you more confidence in what you are doing, your clinical skills, 
would help increase the trust that is given to the pharmacists and maybe 
help them gain more roles in the future.”   Academic Leader 6 
 
There were also examples of positive feedback from patients at HMC.  
“Generally our feedback with like warfarin clinics and such that we have is 
very positive… patients don’t wait for months to get an appointment.” 
Healthcare Policy Leader 2 
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This clinical service was also reported to reduce pressure on physicians.  
“The most important advantage I see from the side of physicians is that it will 
free their time to do more skilled work.”   Academic Leader 6 
 
There was also the view that patient health outcomes were improving.  
“We can see definitely that the anticoagulation outcomes have been better 
with those monitored by pharmacists.”   Academic Leader 6 
 
3. Design quality and packaging 
Mandatory continuing professional development for pharmacists was considered 
a positive development, contributing to the quality of services.  
“I think they are efficient. They keep continuous education so they have 
weekly sessions so they are updating themselves.” 
      Healthcare Policy Leader 1 
 
Furthermore, those involved in the delivery of new and specialised services had 
to undertake further education and training.  
“It is a condensed course that focuses on anticoagulation, how to dose, what 
are the guidelines available and the pathophysiology.” 
Pharmacy Practice Leader 3 
 
While these developments were in HMC settings, it was highlighted that they 
could also be in others such as in primary healthcare centres. 
“They don't have it in primary healthcare, the warfarin clinic. But if the 
volume of patients increase, it can be in primary healthcare, why not?” 
Medical Practice Leader 5 
Inner setting 
1. Structural characteristics 
Many participants highlighted that while the public sector was highly regulated 
with focus on quality of care, the private sector was profit-oriented. 
“The public sector I think it is more structured because they are accredited... 
but in private, nothing. They don't have the policies, they don't have guidelines, 
they are more or less looking for money.”   
Healthcare Policy Leader 3 
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There were contradictory views around the influence and power of the medical 
profession around these developments in clinical pharmacy practice.  
“It is still completely physician driven. There is still a hierarchy.” 
       Academic Leader 8 
“In the cancer centre they have a very intimate collaboration with them 
[physicians] and communication and they really are valued [as an] equivalent 
member of the team. There is no hierarchy.”    
Medical Practice Leader 1 
 
One overwhelming theme was that clinical pharmacy practice varied greatly with 
setting. There was recognition that HMC was much further advanced than other 
settings.  
“As for practice, hospitals are better than community since community is not 
well developed because it lacks assessment and clinical practice.” 
       Pharmacy Practice Leader 6 
“In primary healthcare centres, they are developing now, they are in a better 
position if you compare them to the community pharmacists. But I have to say 
that still they need to work more on themselves.”  
Academic Leader 3 
 
2. Implementation climate 
a. Compatibility 
There was some appreciation that the clinical pharmacy services in HMC could be 
benchmarked to practice in western countries.  
“I left the UK thinking that I had a very good pharmacy service. I have come 
to Qatar and there is a better pharmacy service here in my view.” 
        Healthcare Policy Leader 5 
 
The level of technology and automation available within HMC was considered a 
positive facilitator of development.  
“The level of automation that goes into packages like Cerner is clearly already 
demonstrating that pharmacists can take on a more assertive role on behalf 
of the patients to protect their safety…”   
Healthcare Policy Leader 4 
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While the clinical anticoagulation clinic was well-established, it was noted that 
this took time, with acceleration once physicians had evidence of positive 
outcomes. 
“At the beginning, when they don’t have much experience with it, they may 
be a little bit suspicious… but then after a while, after they saw our abilities 
and how really the patients have been stable and monitored appropriately, I 
think they got more and more confident.”    
Academic Leader 6 
 
Discussion 
Key stakeholders in Qatar perceived clinical pharmacy services as having a 
positive impact on patients’ outcomes, pharmacists’ professional autonomy, and 
the overall healthcare system. However, interviewees did highlight differences in 
the extent of the implementation with tertiary and secondary public care (mainly 
HMC) being the most advanced. Interviewees perceived a lack of awareness of 
the extent of knowledge, training and practice of pharmacists in Qatar and that 
pharmacists were undervalued by patients and the public. There was potential to 
advance clinical pharmacy services, with recognition of facilitators such as the 
skillset and training of pharmacists, potential time release due to automation 
and well-considered implementation processes. 
 
Pharmacists’ contribution to the healthcare system, the multidisciplinary team 
and thus patient care, aligns to the aspirations of the Qatar National Vision,16 its 
associated health strategies17,18 and international efforts for advancing patient-
centred pharmacy practice.1-5  
Several aspects of healthcare setting emerged in this study as being key to the 
development and perceived success of patient-centred clinical pharmacy 
services, relating to CFIR domains of innovation characteristics, inner setting, 
outer setting, characteristics of individuals and process. This is not unique to 
Qatar, with the WHO and the International Pharmaceutical Federation 
highlighting that services are most likely to advance in secondary and tertiary 
care settings.3 There are several likely contributory factors, including close 
multidisciplinary collaboration stimulating mutual trust and respect, ease of 
access to patient data and other key resources, peer support, leadership and 
aspects of governance including role definition, education, training and 
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continuing professional development. Tonna et al.32 noted the importance of 
these factors in defining a guide to planning the implementation of pharmacist 
prescribing, an example of a clinical pharmacy service, in UK hospital practice.  
Barriers for clinical pharmacy implementation in primary care such as lack of 
awareness of pharmacists’ skillset and their potential clinical roles were also 
reported in a qualitative study in Canada.33 The study highlighted that healthcare 
professionals were generally unaware of clinical pharmacy roles, which 
subsequently affected implementation. Similar findings were also reported in 
relation to the community setting. For instance, a systematic review of factors 
influencing national implementation of innovations within community pharmacy 
described three key influences which are: pharmacy staff engagement with the 
proposed services, operationalisation of the innovations (including design, 
complexity and resources needed), and pharmacy staff relationships with 
patients and other healthcare professionals.34 Thus, there is a need to improve 
the provision of clinical pharmacy services in primary and community settings 
which should take into consideration theoretical frameworks, such as the CFIR, 
which highlight the importance of thorough development and the need for 
piloting and continuous evaluation in order to ensure the successful 
implementation of any future clinical pharmacy roles.29 
 
Pharmacist role expansion was facilitated mainly by the perceived level of 
education, training, and motivation that pharmacists possess which can further 
enable them to provide more clinical services in the future (CFIR domain: 
characteristics of individuals). This could be attributed to the increased focus on 
developing pharmacists’ skills in Qatar highlighted in the National Vision and 
National Health Strategy and evidenced by the level of pharmacy education 
offered in the state, the rigorous accreditation, licensing and continuous 
education training pharmacists in Qatar must undergo.22 Similar facilitators 
related to pharmacists’ characteristics, mainly their motivation and knowledge, 
were also reported in a qualitative study with health-system pharmacists and 
managers who experienced the implementation of clinical pharmacy services in 
Brazil, highlighting the importance of having a skilled workforce for the 
successful implementation of such roles.35 
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Implementing more advanced clinical pharmacy services, such as the 
pharmacist-managed anticoagulation clinic, was noted to be met with some 
resistance that was quickly overcome post-implementation. Zaidan et al.36 also 
reported that physicians were more likely to accept new roles performed by 
pharmacists if they had exposure to these contemporary pharmacy services. 
These findings were also reported in the UK when pharmacists advocated for a 
prescribing role in relation to physicians’ concerns around liability and 
pharmacists’ abilities to perform such a role.11 These findings highlight the 
importance of the lived experiences and the need for thorough planning and 
involvement of key stakeholders which also constitutes a key domain of CFIR 
thus highlighting the need to use a theoretical framework in the early 
development of any new innovation. 
 
Despite these advances in clinical pharmacy services in Qatar, interviewees 
noted that the lack of public understanding of pharmacists’ knowledge, training 
and services in general is a major barrier to further role development especially 
within community pharmacy setting where pharmacists are considered to be 
drug dispensers (CFIR domain: outer setting). Low public or patient awareness 
of extended pharmacy services in the community pharmacy setting was also 
reported to be a common finding in the UK according to a recent systematic 
review of the current research literature focusing on perspectives on existing and 
future community pharmacy services.37 This was often related to lack of 
exposure or utilisation of community pharmacy services. Thus, there is a great 
need to improve the public’s awareness of the real extent of pharmacists’ 
knowledge and skillset as well as the different roles they perform in order to 
allow them to expand their clinical services. This was considered especially 
important in Qatar where pharmacists are advocating for more clinical roles 
including prescribing. Recent studies have shown that key health stakeholders 
supported implementation of pharmacist prescribing in Qatar if additional 
training was provided and more efforts were made to increase awareness of the 
different services pharmacists provide in order to overcome potential 
resistance.20,38 
 
This was a theory-driven, qualitative study generating in-depth, rich data of 
stakeholders’ perceptions. Steps were taken to enhance the trustworthiness 
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(credibility and dependability) of the research data and findings, including 
adopting appropriate, well-recognised research methods, encouraging 
interviewees to be frank and talk freely and use of different researchers to 
independently analyse data. The key limitations are that the research outcomes 
are perceptions of stakeholders, rather than objective measures of service 
outcomes and that the findings may not be transferable beyond Qatar.  
 
Further research should focus on the systematic development, implementation 
and evaluation of any future clinical pharmacy service development in Qatar. 
 
Conclusion 
Health-related stakeholders in Qatar have positive perceptions of current clinical 
pharmacy services and support the expansion of pharmacist’s roles. However, 
service development needs to consider the issues of patient and public 
awareness and initially target hospital settings.  
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